Riley J. Batchelor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Riley J. Batchelor has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
Angela Brennan
9 shared publicationsDion Stub
7 shared publicationsDiem Dinh
6 shared publications- Dion Stub
Monash University
6 shared publications - Jeffrey Lefkovits
The Royal Melbourne Hospital, Australia
5 shared publications Andrew Ajani
Department of Cardiology, Royal Melbourne Hospital Melbourne Australia
4 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (11) , 1554-1561
After-Hours Versus In-Hours Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
- 28 August 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (11) , 1554-1561
After-Hours Versus In-Hours Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
- 18 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Aorto‐Ostial Lesion Percutaneous Coronary Intervention: Clinical Characteristics, Predictors and Clinical Outcomes
Background: Aorto‐ostial coronary lesions represent a high‐risk subset of coronary disease because of fibrocalcific disease, elastic recoil, and difficulty achieving precise stent positioning. Percutaneous coronary intervention (PCI) of these lesions may therefore be associated with less favourable outcomes than of proximal non‐ostial lesions. Furthermore, ostial left main coronary artery (LMCA) and right coronary artery (RCA) lesions differ in anatomy and myocardium at risk. Aims: To compare procedural practice and outcomes of aorto‐ostial versus proximal non‐ostial PCI. Methods: We analysed patients from the multicentre Melbourne Interventional Group Registry who underwent PCI between 2005 and 2020. Patients treated for ostial LMCA or ostial RCA lesions (aorto‐ostial lesion [AOL] group) were compared with those undergoing PCI for proximal non‐ostial LMCA or RCA lesions (non‐AOL group). The primary outcome was long‐term mortality. Secondary outcomes were in‐hospital and 30‐day major adverse cardiovascular events (MACE), with multivariable logistic regression used to identify independent predictors of 30‐day MACE. Vessel‐specific analysis compared ostial and non‐ostial LMCA and RCA PCI separately. Results: Among 4683 PCI procedures, 538 (11.5%) underwent PCI for AOL and 4145 (88.5%) for proximal non‐ostial LMCA or RCA lesions. Patients in the AOL group were older (70.1 vs. 65.0 years, p < 0.001), more often female (37.7% vs. 25.5%, p < 0.001), and had a greater burden of comorbidity and lesion complexity. Rotational atherectomy (4.5% vs. 1.2%, p < 0.001) and intravascular ultrasound (5.9% vs. 1.2%, p < 0.001) were used more frequently in the AOL group, although overall use was low. AOL location was not independently associated with 30‐day MACE (adjusted OR 0.93, 95% CI 0.60−1.45; p = 0.76). Long‐term survival was lower in the pooled AOL cohort (log‐rank p < 0.001); vessel‐specific analysis showed no difference for LMCA PCI ( p = 0.69), whereas survival was lower after ostial RCA PCI ( p < 0.001). Conclusions: Patients undergoing AOL PCI had a higher‐risk clinical profile but similar adjusted early outcomes. In vessel‐specific analyses, the pooled long‐term survival difference appeared predominantly attributable to the RCA cohort, with no difference between ostial and non‐ostial LMCA PCI. This may reflect differences in baseline patient risk rather than excess periprocedural risk alone.
- 18 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Aorto‐Ostial Lesion Percutaneous Coronary Intervention: Clinical Characteristics, Predictors and Clinical Outcomes
Background: Aorto‐ostial coronary lesions represent a high‐risk subset of coronary disease because of fibrocalcific disease, elastic recoil, and difficulty achieving precise stent positioning. Percutaneous coronary intervention (PCI) of these lesions may therefore be associated with less favourable outcomes than of proximal non‐ostial lesions. Furthermore, ostial left main coronary artery (LMCA) and right coronary artery (RCA) lesions differ in anatomy and myocardium at risk. Aims: To compare procedural practice and outcomes of aorto‐ostial versus proximal non‐ostial PCI. Methods: We analysed patients from the multicentre Melbourne Interventional Group Registry who underwent PCI between 2005 and 2020. Patients treated for ostial LMCA or ostial RCA lesions (aorto‐ostial lesion [AOL] group) were compared with those undergoing PCI for proximal non‐ostial LMCA or RCA lesions (non‐AOL group). The primary outcome was long‐term mortality. Secondary outcomes were in‐hospital and 30‐day major adverse cardiovascular events (MACE), with multivariable logistic regression used to identify independent predictors of 30‐day MACE. Vessel‐specific analysis compared ostial and non‐ostial LMCA and RCA PCI separately. Results: Among 4683 PCI procedures, 538 (11.5%) underwent PCI for AOL and 4145 (88.5%) for proximal non‐ostial LMCA or RCA lesions. Patients in the AOL group were older (70.1 vs. 65.0 years, p < 0.001), more often female (37.7% vs. 25.5%, p < 0.001), and had a greater burden of comorbidity and lesion complexity. Rotational atherectomy (4.5% vs. 1.2%, p < 0.001) and intravascular ultrasound (5.9% vs. 1.2%, p < 0.001) were used more frequently in the AOL group, although overall use was low. AOL location was not independently associated with 30‐day MACE (adjusted OR 0.93, 95% CI 0.60−1.45; p = 0.76). Long‐term survival was lower in the pooled AOL cohort (log‐rank p < 0.001); vessel‐specific analysis showed no difference for LMCA PCI ( p = 0.69), whereas survival was lower after ostial RCA PCI ( p < 0.001). Conclusions: Patients undergoing AOL PCI had a higher‐risk clinical profile but similar adjusted early outcomes. In vessel‐specific analyses, the pooled long‐term survival difference appeared predominantly attributable to the RCA cohort, with no difference between ostial and non‐ostial LMCA PCI. This may reflect differences in baseline patient risk rather than excess periprocedural risk alone.
- 12 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1194-1196
Clearing cardiac patients for take-off: is the evidence fit to fly?
- 12 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (7) , 1194-1196
Clearing cardiac patients for take-off: is the evidence fit to fly?
- Open Access
- 5 June 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (9) , 1313-1320
Cost-Effectiveness of Impella Versus Veno-Arterial Extracorporeal Membrane Oxygenation in Patients With Acute Myocardial Infarction Cardiogenic Shock
- 5 June 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (9) , 1313-1320
Open AccessCost-Effectiveness of Impella Versus Veno-Arterial Extracorporeal Membrane Oxygenation in Patients With Acute Myocardial Infarction Cardiogenic Shock
- Open Access
- 2 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (2)
Successful use of methylene blue following out of hospital cardiac arrest: a case report
Background: Cardiac arrest and cardiogenic shock are medical emergencies with poor survival rates despite improvements in advanced life support and resuscitation techniques. Case summary: We present the case of a 44-year-old woman with ischaemic cardiomyopathy who suffered a prolonged out-of-hospital cardiac arrest due to ventricular tachycardia. Despite high-dose catecholamines and vasopressin, the patient had persistent hypotension and elevated vasoactive-inotropic requirements. Haemodynamic monitoring revealed features consistent with post-arrest vasoplegia. Two low-dose boluses of methylene blue (0.25 mg/kg) were administered, resulting in a rapid and sustained improvement in cardiac output, index, and blood pressure, alongside a marked reduction in vasoactive support. The patient made a full neurological recovery and was discharged home. Discussion: While already established in vasopressor resistant septic shock and post-cardiopulmonary bypass vasoplegia, this case highlights the potential role of methylene blue as an adjunct therapy in post out of hospital cardiac arrest vasoplegia, particularly when conventional therapies fail. The dose of methylene blue used was substantially lower than that reported in prior studies of sepsis and cardiac surgery. Further studies are warranted to define the timing, dosing, and clinical impact of methylene blue in this setting.
- 2 February 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (2)
Open AccessSuccessful use of methylene blue following out of hospital cardiac arrest: a case report
Background: Cardiac arrest and cardiogenic shock are medical emergencies with poor survival rates despite improvements in advanced life support and resuscitation techniques. Case summary: We present the case of a 44-year-old woman with ischaemic cardiomyopathy who suffered a prolonged out-of-hospital cardiac arrest due to ventricular tachycardia. Despite high-dose catecholamines and vasopressin, the patient had persistent hypotension and elevated vasoactive-inotropic requirements. Haemodynamic monitoring revealed features consistent with post-arrest vasoplegia. Two low-dose boluses of methylene blue (0.25 mg/kg) were administered, resulting in a rapid and sustained improvement in cardiac output, index, and blood pressure, alongside a marked reduction in vasoactive support. The patient made a full neurological recovery and was discharged home. Discussion: While already established in vasopressor resistant septic shock and post-cardiopulmonary bypass vasoplegia, this case highlights the potential role of methylene blue as an adjunct therapy in post out of hospital cardiac arrest vasoplegia, particularly when conventional therapies fail. The dose of methylene blue used was substantially lower than that reported in prior studies of sepsis and cardiac surgery. Further studies are warranted to define the timing, dosing, and clinical impact of methylene blue in this setting.
- 16 January 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (5) , 1303-1311
Clinical Outcomes in Young Patients Undergoing Percutaneous Coronary Intervention
Background: Young adults undergoing percutaneous coronary intervention (PCI) are often perceived as low risk, yet long‐term outcome data in this population are limited. Understanding predictors of adverse events in this group may uncover important targets for improving procedural and postprocedural care. Aims: To evaluate the incidence and predictors of 12‐month mortality and major adverse cardiovascular events (MACE) in a contemporary Australian cohort of young patients undergoing PCI. Methods: We analyzed data from the Victorian Cardiac Outcomes Registry (VCOR), a multicenter state‐wide PCI registry, including all patients aged 18–55 years who underwent PCI between 2014 and 2023. Patients with out‐of‐hospital cardiac arrest or cardiogenic shock were excluded. The primary outcome was 12‐month all‐cause mortality; secondary outcomes included in‐hospital events and 30‐day major adverse cardiovascular events (MACE). Results: Among 16,410 patients, most were aged 45−55 ( n = 13,188/16,410; 80.4%), and the majority presented with acute coronary syndromes ( n = 10,792/16,410; 65.8%). The 12‐month mortality was 1.0%, with no difference across age subgroups. Independent predictors for long‐term mortality included eGFR ≤ 30 (HR 6.99; 95% CI 4.98–9.80), left ventricular ejection fraction < 35% (HR 5.35; 95% CI 4.01–7.13), diabetes (HR 1.65; 95% CI 1.33–2.03), and female sex (HR 1.42; 95% CI 1.14–1.78). Use of dual antiplatelet therapy at 30 days was lower in those who died (49.4% vs. 88.9%, p < 0.001). Procedural factors such as femoral access and use of bare‐metal stents were also more common in this group. Stent thrombosis, stroke, and major bleeding were disproportionately represented among those who died. Conclusion: Although 12‐month mortality after PCI in young adults is low, patients with comorbidities such as diabetes, chronic kidney disease, and left ventricular dysfunction experience disproportionately worse outcomes. These findings highlight the need for improved adherence to evidence‐based secondary prevention in this high‐risk subset.
- 16 January 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 107 (5) , 1303-1311
Clinical Outcomes in Young Patients Undergoing Percutaneous Coronary Intervention
Background: Young adults undergoing percutaneous coronary intervention (PCI) are often perceived as low risk, yet long‐term outcome data in this population are limited. Understanding predictors of adverse events in this group may uncover important targets for improving procedural and postprocedural care. Aims: To evaluate the incidence and predictors of 12‐month mortality and major adverse cardiovascular events (MACE) in a contemporary Australian cohort of young patients undergoing PCI. Methods: We analyzed data from the Victorian Cardiac Outcomes Registry (VCOR), a multicenter state‐wide PCI registry, including all patients aged 18–55 years who underwent PCI between 2014 and 2023. Patients with out‐of‐hospital cardiac arrest or cardiogenic shock were excluded. The primary outcome was 12‐month all‐cause mortality; secondary outcomes included in‐hospital events and 30‐day major adverse cardiovascular events (MACE). Results: Among 16,410 patients, most were aged 45−55 ( n = 13,188/16,410; 80.4%), and the majority presented with acute coronary syndromes ( n = 10,792/16,410; 65.8%). The 12‐month mortality was 1.0%, with no difference across age subgroups. Independent predictors for long‐term mortality included eGFR ≤ 30 (HR 6.99; 95% CI 4.98–9.80), left ventricular ejection fraction < 35% (HR 5.35; 95% CI 4.01–7.13), diabetes (HR 1.65; 95% CI 1.33–2.03), and female sex (HR 1.42; 95% CI 1.14–1.78). Use of dual antiplatelet therapy at 30 days was lower in those who died (49.4% vs. 88.9%, p < 0.001). Procedural factors such as femoral access and use of bare‐metal stents were also more common in this group. Stent thrombosis, stroke, and major bleeding were disproportionately represented among those who died. Conclusion: Although 12‐month mortality after PCI in young adults is low, patients with comorbidities such as diabetes, chronic kidney disease, and left ventricular dysfunction experience disproportionately worse outcomes. These findings highlight the need for improved adherence to evidence‐based secondary prevention in this high‐risk subset.
- 12 December 2025
- Published by Wiley in Anaesthesia
- Vol. 81 (4) , 570-579
Peri‐operative risk of non‐cardiac surgery in patients with aortic stenosis: a systematic review and meta‐analysis
Summary: Introduction: Aortic stenosis is a risk factor for adverse outcomes following non‐cardiac surgery; however, existing data regarding peri‐operative morbidity and mortality in this patient cohort remain conflicted. This systematic review and meta‐analysis aimed to quantify the peri‐operative risks in patients with aortic stenosis undergoing non‐cardiac surgery. Methods: Following the development of our search strategy, we searched databases for relevant studies. The primary endpoint was all‐cause in‐hospital or 30‐day mortality associated with aortic stenosis in patients undergoing non‐cardiac surgery. Secondary endpoints included: myocardial infarction; heart failure; stroke; delirium; venous thromboembolism; and acute kidney injury. Results: Nineteen studies involving 100,486 patients were included. The estimated all‐cause mortality was 3.8% (95%CI 3.7–3.9%) for patients with any degree of aortic stenosis and 9.6% (95%CI 7.7–12.1%) for those with severe aortic stenosis. A meta‐analysis of 14 comparative studies involving 2,885,254 patients revealed significantly increased mortality in patients with aortic stenosis compared with those without aortic stenosis (relative risk 1.58, 95%CI 1.18–2.12, p < 0.001). Aortic stenosis was also associated with an elevated risk of postoperative myocardial infarction (relative risk 1.79, 95%CI 1.2–2.67, p < 0.001) and heart failure (relative risk 2.06, 95%CI 1.19–3.59, p < 0.001). Discussion: Aortic stenosis in patients undergoing non‐cardiac surgery is associated with a three‐fold relative increase in the risk of mortality. These results highlight the need for further delineation of which surgical procedures are associated with the greatest risk of poor peri‐operative outcomes to guide heightened surveillance protocols, optimised peri‐operative management and thresholds for pre‐operative intervention.
- 12 December 2025
- Published by Wiley in Anaesthesia
- Vol. 81 (4) , 570-579
Peri‐operative risk of non‐cardiac surgery in patients with aortic stenosis: a systematic review and meta‐analysis
Summary: Introduction: Aortic stenosis is a risk factor for adverse outcomes following non‐cardiac surgery; however, existing data regarding peri‐operative morbidity and mortality in this patient cohort remain conflicted. This systematic review and meta‐analysis aimed to quantify the peri‐operative risks in patients with aortic stenosis undergoing non‐cardiac surgery. Methods: Following the development of our search strategy, we searched databases for relevant studies. The primary endpoint was all‐cause in‐hospital or 30‐day mortality associated with aortic stenosis in patients undergoing non‐cardiac surgery. Secondary endpoints included: myocardial infarction; heart failure; stroke; delirium; venous thromboembolism; and acute kidney injury. Results: Nineteen studies involving 100,486 patients were included. The estimated all‐cause mortality was 3.8% (95%CI 3.7–3.9%) for patients with any degree of aortic stenosis and 9.6% (95%CI 7.7–12.1%) for those with severe aortic stenosis. A meta‐analysis of 14 comparative studies involving 2,885,254 patients revealed significantly increased mortality in patients with aortic stenosis compared with those without aortic stenosis (relative risk 1.58, 95%CI 1.18–2.12, p < 0.001). Aortic stenosis was also associated with an elevated risk of postoperative myocardial infarction (relative risk 1.79, 95%CI 1.2–2.67, p < 0.001) and heart failure (relative risk 2.06, 95%CI 1.19–3.59, p < 0.001). Discussion: Aortic stenosis in patients undergoing non‐cardiac surgery is associated with a three‐fold relative increase in the risk of mortality. These results highlight the need for further delineation of which surgical procedures are associated with the greatest risk of poor peri‐operative outcomes to guide heightened surveillance protocols, optimised peri‐operative management and thresholds for pre‐operative intervention.
- Open Access
- 25 November 2025
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102016
Non-invasive versus invasive estimation of left ventricular wall stress with cardiac magnetic resonance imaging in severe aortic stenosis
- 25 November 2025
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102016
Open AccessNon-invasive versus invasive estimation of left ventricular wall stress with cardiac magnetic resonance imaging in severe aortic stenosis
- 1 November 2025
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 34 (12) , 1409-1416
Percutaneous Femoral Arterial Closure Following Decannulation of Venoarterial Extracorporeal Membrane Oxygenation Using the MANTA Vascular Closure Device
- 1 November 2025
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 34 (12) , 1409-1416
Percutaneous Femoral Arterial Closure Following Decannulation of Venoarterial Extracorporeal Membrane Oxygenation Using the MANTA Vascular Closure Device
- Open Access
- 8 April 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 165-173
Dual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention for Acute Coronary Syndrome: Prevalence and Outcomes in Contemporary Practice
Background: Dual antiplatelet therapy (DAPT) is standard following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Preloading is the practice of administering both aspirin and a P2Y 12 inhibitor before PCI. DAPT preloading is common practice, however clinical trial evidence demonstrating benefit is lacking. Aims: This study aimed to examine the prevalence and associated clinical outcomes of DAPT before PCI for ACS in a contemporary population of Australian patients. Methods: Data on consecutive PCI procedures from patients included in the Victorian Cardiac Outcomes Registry (VCOR) from 2014 to 2021 was collected and stratified by administration of DAPT before PCI versus single, or no, antiplatelet therapy. Results: In total, 42,453 consecutive PCI procedures for ACS were included. Of these, 33,520 (79%) patients were either preloaded or already on DAPT before PCI. Patients on DAPT were younger (63.9 vs. 65.1, p < 0.001) and generally had fewer comorbidities. Unadjusted outcomes were more favorable with pre‐loading with lower in‐hospital mortality with DAPT (2.6% vs. 5.6%, p < 0.001), and 30‐day cardiovascular mortality (0.3% vs. 0.4%, p = 0.039). 30‐day major adverse cardiovascular events (MACE) (5.5% vs. 8.8%, p < 0.001) was similarly lower in the preloaded group. Major bleeding in hospital was less common in patients on DAPT (1.0% vs. 1.7%, p < 0.001). However, following adjustment for covariates, there was no difference in in‐hospital or 30‐day all‐cause mortality, MACE or stent thrombosis between groups. Conclusions: DAPT before PCI is common in ACS but not independently associated with improvements in in‐hospital mortality, MACE, or stent thrombosis.
- 8 April 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (1) , 165-173
Open AccessDual Antiplatelet Therapy Prior to Percutaneous Coronary Intervention for Acute Coronary Syndrome: Prevalence and Outcomes in Contemporary Practice
Background: Dual antiplatelet therapy (DAPT) is standard following percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Preloading is the practice of administering both aspirin and a P2Y 12 inhibitor before PCI. DAPT preloading is common practice, however clinical trial evidence demonstrating benefit is lacking. Aims: This study aimed to examine the prevalence and associated clinical outcomes of DAPT before PCI for ACS in a contemporary population of Australian patients. Methods: Data on consecutive PCI procedures from patients included in the Victorian Cardiac Outcomes Registry (VCOR) from 2014 to 2021 was collected and stratified by administration of DAPT before PCI versus single, or no, antiplatelet therapy. Results: In total, 42,453 consecutive PCI procedures for ACS were included. Of these, 33,520 (79%) patients were either preloaded or already on DAPT before PCI. Patients on DAPT were younger (63.9 vs. 65.1, p < 0.001) and generally had fewer comorbidities. Unadjusted outcomes were more favorable with pre‐loading with lower in‐hospital mortality with DAPT (2.6% vs. 5.6%, p < 0.001), and 30‐day cardiovascular mortality (0.3% vs. 0.4%, p = 0.039). 30‐day major adverse cardiovascular events (MACE) (5.5% vs. 8.8%, p < 0.001) was similarly lower in the preloaded group. Major bleeding in hospital was less common in patients on DAPT (1.0% vs. 1.7%, p < 0.001). However, following adjustment for covariates, there was no difference in in‐hospital or 30‐day all‐cause mortality, MACE or stent thrombosis between groups. Conclusions: DAPT before PCI is common in ACS but not independently associated with improvements in in‐hospital mortality, MACE, or stent thrombosis.